The SGLT2 inhibitor node included dedicated renal outcome trials (CREDENCE, DAPA-CKD, EMPA-KIDNEY) and heart failure trials (DAPA-HF, EMPEROR-Reduced), resulting in a lower weighted mean eGFR (65.2 mL/minute/1.73 m2) compared to the GLP-1 receptor agonist node (76.8 mL/minute/1.73 m2). This evidence concerns the gene SLC5A2 and chronic kidney disease.